MedicalResearch.com Interview with:
Daniel J. Wallace M.D., FACP, MACR
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Beverly Hills, Ca 90211
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This is the first positive study of systemic lupus erythematosus (SLE) using baricitinib, a small oral molecule that blocks the JAK system.
The human kinome consists of 500 genes and helps regulate cell surface receptor interaction. While agents that inhibit certain pathways are approved for rheumatoid arthritis and certain malignancies, this is the first study of its kind in SLE.
MedicalResearch.com: What should readers take away from your report?
Response: Baricitinib improved joint manifestations and an overall index known as the SRI-4 which is a composite score that measures a variety of lupus activity measures in the 4 mg but not the 2 mg dosing. It also had an excellent safety profile. Over 20 Phase II and III prior trials have failed in systemic lupus erythematosus.
Baricitinib may be an effective agent for this disorder.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: A phase III trial of baricitinib will be starting later this year.
Disclosures: Consultant for Lilly
Wallace, Daniel J et al.
The Lancet , Volume 392 , Issue 10143 , 222 – 231